FOXO TechnologiesFOXO -50.00% EBITDA Margin % is -6.02% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, FOXO Technologies ranks worse than 88.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. FOXO Technologies's EBITDA for the
three
months ended in Mar. 2026 was $-0.31 Mil. FOXO Technologies's Revenue for the
three
months ended in Mar. 2026 was $5.17 Mil. Therefore, FOXO Technologies's EBITDA margin for the quarter that ended in Mar. 2026 was -6.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
FOXO Technologies EBITDA Margin % Related Terms
FOXO Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for FOXO Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FOXO vs WORX, MSPR, ESSID: EBITDA Margin % Comparison
For the Health Information Services subindustry, FOXO Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FOXO Technologies EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, FOXO Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where FOXO Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FOXO Technologies (FOXO) has a EBITDA Margin % of -6.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on FOXO Technologies and its competitors. According to the industry distribution chart, FOXO Technologies ranks #589 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 88.2%.
Is FOXO Technologies' EBITDA Margin % too high?
FOXO Technologies' current EBITDA Margin % is -6.02%. Based on the distribution chart, FOXO Technologies ranks #589 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does FOXO Technologies' EBITDA Margin % compare to WORX and MSPR?
According to the Healthcare Providers & Services industry distribution chart, FOXO Technologies ranks #589 out of 668 companies for EBITDA Margin %. This places FOXO Technologies in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on FOXO Technologies and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. FOXO Technologies's current EBITDA Margin % is -6.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FOXO Technologies stock overvalued right now?
Based on GuruFocus' analysis, FOXO Technologies (FOXO) is currently considered Possible Value Trap. The stock's GF Value™ is $5.87, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current EBITDA Margin % is -6.02%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For FOXO Technologies (FOXO), the current EBITDA Margin % is -6.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FOXO Technologies Inc is a healthcare services and technology company. It currently operates four synergistic divisions: (i) a rural hospital division; (ii) a mental and behavioral health division; (iii) an information, data and biospecimen sourcing division; and (iv) an epigenetics diagnostics and interpretation division. The Company manages and classifies its business into three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs. Myrtle, RCHI and SCCH operate under the Healthcare segment and Vector operates under the Life Science Services segment. The company generates majority of its revenue from Healthcare segment. It includes RCHI's hospital, BSF, has 25 inpatient beds, and a 24/7 emergency department and provides ancillary services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOXO has been successfully added to your 